Home > Research > Publications & Outputs > Clearance of interstitial fluid (ISF) and CSF (...

Links

Text available via DOI:

View graph of relations

Clearance of interstitial fluid (ISF) and CSF (CLIC) group‐part of Vascular Professional Interest Area (PIA), updates in 2022‐2023. Cerebrovascular disease and the failure of elimination of Amyloid‐β from the brain and retina with age and Alzheimer's disease: Opportunities for therapy

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published
  • Louise Kelly
  • Christopher Brown
  • Daniel Michalik
  • Roxana Aldea
  • Nivedita Agarwal
  • Rami Salib
  • Aiman Alzetani
  • Douglas W Ethell
  • Scott E. Counts
  • Mony de Leon
  • Silvia Fossati
  • Maya Koronyo‐Hamaoui
  • Fabrizio Piazza
  • Steven A. Rich
  • Frank J. Wolters
  • Heather Snyder
  • Ozama Ismail
  • Fanny Elahi
  • Steven T. Proulx
  • Ajay Verma
  • Hilary Wunderlich
  • Mareike Haack
  • Jean Cosme Dodart
  • Norman Mazer
  • Roxana O. Carare
Close
<mark>Journal publication date</mark>21/02/2024
<mark>Journal</mark>Alzheimer's and Dementia : the journal of the Alzheimer's Association
Issue number2
Volume20
Pages (from-to)1421-1435
Publication StatusPublished
Early online date28/10/23
<mark>Original language</mark>English

Abstract

This editorial summarizes advances from the Clearance of Interstitial Fluid and Cerebrospinal Fluid (CLIC) group, within the Vascular Professional Interest Area (PIA) of the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART). The overarching objectives of the CLIC group are to: (1) understand the age‐related physiology changes that underlie impaired clearance of interstitial fluid (ISF) and cerebrospinal fluid (CSF) (CLIC); (2) understand the cellular and molecular mechanisms underlying intramural periarterial drainage (IPAD) in the brain; (3) establish novel diagnostic tests for Alzheimer's disease (AD), cerebral amyloid angiopathy (CAA), retinal amyloid vasculopathy, amyloid‐related imaging abnormalities (ARIA) of spontaneous and iatrogenic CAA‐related inflammation (CAA‐ri), and vasomotion; and (4) establish novel therapies that facilitate IPAD to eliminate amyloid β (Aβ) from the aging brain and retina, to prevent or reduce AD and CAA pathology and ARIA side events associated with AD immunotherapy.